


The meriT-1 Study

Study Highlights

- Principal Investigator: Dr. Sameer Dani
- The meriT-1 was a first-in-human, single-center trial which showed favourable results of BioMime sirolimus-eluting coronary stent system in treatment of *de novo* coronary artery lesions
- Two-year clinical follow-up with Angiographic analysis at 8-month



❖ Study Design

A prospective, non-randomized, single-arm, first-in-man trial



30 subjects were enrolled



Angiographic follow-up at 8 months

Analysed by Cardiovascular Research Centre, Sao Paulo, Brazil



Clinical follow-up at 12-month and 24-month

❖ Study Results




Figure 1: Clinical presentation of study population, (%)




Figure 2: Lesion characteristics of study population, (%)




Figure 3: Cumulative frequency distribution curve for MLD at baseline, final (in-stent) and FU (in-stent) for patients with serial angiographic analysis

❖ References

1. ClinicalTrials.gov – NCT01507519
<https://clinicaltrials.gov/ct2/show/NCT01507519>
2. CTRI Number: CTRI/2016/11/007475 at
<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=15684&EncHid=&userName=>
3. Clinical Trials Department - Meril Life Sciences. BioMime – A Sirolimus-eluting Coronary Stent System for the Treatment of Patients with De Novo Coronary Lesions – meriT-1 Report. *Interventional Cardiology*, 2011;6(1):39–43.
4. Seth A. AS-003 Moving Towards Biomimicry-Development of Novel BioMime™ Sirolimus Eluting Coronary Stent System. *Journal of the American Journal of Cardiology*. 2011;107(8):1A-2A.
5. De Abreu-Silva E, Costa R, Dani S, Lima M, JOSHI H, SHAH J, et al. TCT-578 First-in-human Evaluation of a Novel Sirolimus-eluting Stent with a Bioabsorbable Polymer for the Treatment of Single, De Novo, Non-complex Coronary Lesions. *Journal of the American College of Cardiology*. 2012;60(17 Supplement):B168.
6. Dani S, Costa RA, Joshi H, Shah J, Pandya R, Virmani R, Sheiban I, Bhatt S, Abizaid A. First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels-results from the meriT-1 trial. *EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2013 Aug; 9 (4):493-500.
7. Costa RA, Abizaid A, Dani S, Joshi H, Wander GS, Hardas S, et al. TCT-212 Efficacy of the Novel BioMime Sirolimus-Eluting Stents with a Biodegradable Polymer in the Treatment of De Novo Coronary Lesions: An Angiographic Subanalysis of the Combined meriT-1 and meriT-2 Prospective Clinical Trials. *Journal of the American College of Cardiology*. 2013;62(18 Supplement 1):B68.
8. Bhatt S, Gujarathi S, De Benedictis M. Innovative DES technologies from Meril. *Minerva cardioangiologica* 2015;63:441-8.
9. Presented by Roberto Botelho. Outcomes With a Thin-Strut PLLA-Based Sirolimus-Eluting Stent 1: BioMime, At TCT 2017
<https://www.tctmd.com/slide/outcomes-thin-strut-plla-based-sirolimus-eluting-stent-1-biomime>